Latest & greatest articles for Superficial Thrombophlebitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Superficial Thrombophlebitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Superficial Thrombophlebitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Superficial Thrombophlebitis

1. Treatment of Lower Extremity Superficial Thrombophlebitis. (PubMed)

Treatment of Lower Extremity Superficial Thrombophlebitis. Which treatments for lower extremity superficial thrombophlebitis (ST) are associated with lower rates of venous thromboembolic events (VTEs) vs placebo?A dose of 2.5 mg of fondaparinux administered subcutaneously once daily for 45 days is associated with fewer cases of symptomatic VTE without an increase in major bleeding vs placebo. Low-molecular-weight heparin (LMWH) and nonsteroidal anti-inflammatory drugs (NSAIDs) are associated

2018 JAMA

2. Treatment for superficial thrombophlebitis of the leg. (PubMed)

Treatment for superficial thrombophlebitis of the leg. The optimal treatment of superficial thrombophlebitis (ST) of the legs remains poorly defined. While improving or relieving the local painful symptoms, treatment should aim at preventing venous thromboembolism (VTE), which might complicate the natural history of ST. This is the third update of a review first published in 2007.To assess the efficacy and safety of topical, medical, and surgical treatments for ST of the leg in improving local (...) or objective diagnosis of a thrombus in a superficial vein.Two authors assessed the trials for inclusion in the review, extracted the data, and assessed the quality of the studies. Data were independently extracted from the included studies and any disagreements resolved by consensus. We assessed the quality of the evidence using the GRADE approach.We identified three additional trials (613 participants), therefore this update considered 33 studies involving 7296 people with ST of the legs. Treatment

2018 Cochrane

3. Superficial vein thrombophlebitis

Superficial vein thrombophlebitis Superficial vein thrombophlebitis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Superficial vein thrombophlebitis Last reviewed: February 2019 Last updated: May 2018 Summary Superficial vein thrombophlebitis (SVT) of the lower limb is most often a complication of varicose veins. Duplex ultrasonography should be performed on all patients with suspected SVT of the lower limb (...) , as concomitant deep vein thrombosis (DVT) may be present. Underlying prothrombotic conditions should be sought in cases of recurrent SVT and migratory SVT, especially in the absence of varicose veins. Anticoagulation to prevent venous thromboembolic complications (DVT or pulmonary embolism) is warranted, especially in patients with SVT near the saphenofemoral junction, or when the superficial thrombus is 5 cm or greater in length. Definition Superficial vein thrombophlebitis (SVT) refers to thrombus

2018 BMJ Best Practice

4. Thrombophlebitis - superficial

Thrombophlebitis - superficial Thrombophlebitis - superficial - NICE CKS Share Thrombophlebitis - superficial: Summary Superficial thrombophlebitis is a common disorder that occurs when a superficial vein becomes inflamed (phlebitis) and the blood within it clots (venous thrombosis). It may be spontaneous or be associated with one or more risk factors, such as varicose veins, intravenous cannulation, or previous superficial phlebitis. Septic thrombophlebitis occurs when superficial (...) thrombophlebitis becomes infected. It most commonly presents as a localized infection but, occasionally, this infection can spread to the rest of the body and become life threatening. Migratory thrombophlebitis is thrombophlebitis that recurs in the same vein, a different vein, or multiple veins. It is often associated with a serious underlying cause (such as cancer) and warrants further investigation. The prognosis of superficial thrombophlebitis is good. It usually settles within 3–4 weeks, although

2017 NICE Clinical Knowledge Summaries

5. Treatment for superficial infusion thrombophlebitis of the upper extremity. (PubMed)

Treatment for superficial infusion thrombophlebitis of the upper extremity. Although superficial thrombophlebitis of the upper extremity represents a frequent complication of intravenous catheters inserted into the peripheral veins of the forearm or hand, no consensus exists on the optimal management of this condition in clinical practice.To summarise the evidence from randomised clinical trials (RCTs) concerning the efficacy and safety of (topical, oral or parenteral) medical therapy (...) of superficial thrombophlebitis of the upper extremity.The Cochrane Vascular Group Trials Search Co-ordinator searched the Specialised Register (last searched April 2015) and the Cochrane Register of Studies (2015, Issue 3). Clinical trials registries were searched up to April 2015.RCTs comparing any (topical, oral or parenteral) medical treatment to no intervention or placebo, or comparing two different medical interventions (e.g. a different variant scheme or regimen of the same intervention or a different

Full Text available with Trip Pro

2015 Cochrane

6. Treatment of lower extremity superficial thrombophlebitis. (PubMed)

Treatment of lower extremity superficial thrombophlebitis. What treatments for lower extremity superficial thrombophlebitis are associated with lower rates of venous thromboembolic events (VTE), major bleeding, and superficial venous thrombosis extension?Fondaparinux (2.5 mg) subcutaneously once daily for 45 days is associated with fewer symptomatic VTEs and lower rates of superficial venous thrombosis extension and recurrence with no increases in major bleeding compared with placebo. Low (...) -molecular-weight heparin and nonsteroidal anti-inflammatory drugs are associated with lower rates of superficial thrombophlebitis extension or recurrence, but data regarding symptomatic VTEs are inconclusive.

Full Text available with Trip Pro

2014 JAMA Controlled trial quality: uncertain

7. Systematic review: Prophylactic dose fondaparinux for 6?weeks in superficial thrombophlebitis of the legs reduces the risk for symptomatic thromboembolic complications

Systematic review: Prophylactic dose fondaparinux for 6?weeks in superficial thrombophlebitis of the legs reduces the risk for symptomatic thromboembolic complications Prophylactic dose fondaparinux for 6 weeks in superficial thrombophlebitis of the legs reduces the risk for symptomatic thromboembolic complications | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Prophylactic dose fondaparinux for 6 weeks in superficial thrombophlebitis

2013 Evidence-Based Medicine

8. Review: Fondaparinux reduces VTE and recurrence in superficial thrombophlebitis of the leg. (PubMed)

Review: Fondaparinux reduces VTE and recurrence in superficial thrombophlebitis of the leg. 22910958 2012 10 19 2012 08 22 1539-3704 157 4 2012 Aug 21 Annals of internal medicine Ann. Intern. Med. ACP Journal Club: review: fondaparinux reduces VTE and recurrence in superficial thrombophlebitis of the leg. JC2-4 10.7326/0003-4819-157-4-201208210-02004 Stevens Scott M SM Intermountain Medical Center and University of Utah Murray, Utah, USA. eng Comment Journal Article United States Ann Intern Med

2012 Annals of Internal Medicine

9. Treatment of Superficial Thrombophlebitis. (PubMed)

Treatment of Superficial Thrombophlebitis. 21268736 2011 02 04 2018 12 01 1533-4406 364 4 2011 01 27 The New England journal of medicine N. Engl. J. Med. Treatment of superficial thrombophlebitis. 380; author reply 380-1; discussion 381 10.1056/NEJMc1011872 Loewenstein Roy R eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Polysaccharides J177FOW5JL Fondaparinux AIM IM N Engl J Med. 2010 Sep 23;363(13):1222-32 20860504 Anticoagulants therapeutic use

Full Text available with Trip Pro

2011 NEJM

10. Treatment of Superficial Thrombophlebitis. (PubMed)

Treatment of Superficial Thrombophlebitis. 21268737 2011 02 04 2018 12 01 1533-4406 364 4 2011 01 27 The New England journal of medicine N. Engl. J. Med. Treatment of superficial thrombophlebitis. 380; author reply 380-1; discussion 381 10.1056/NEJMc1011872 Brodin-Sartorius Albane A Martinez Frank F Legendre Christophe C eng Case Reports Letter Comment United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Polysaccharides J177FOW5JL Fondaparinux AIM IM N Engl J Med. 2010 Sep 23;363(13

Full Text available with Trip Pro

2011 NEJM

11. Treatment of Superficial Thrombophlebitis. (PubMed)

Treatment of Superficial Thrombophlebitis. Treatment of Superficial Thrombophlebitis | NEJM logo-32 logo-40 logo-60 Follow Us Stay connected to what's important in medical research and clinical practice Subscribe to the most trusted and influential source of medical knowledge Already a subscriber? or Search site Keyword Specialties Selected specialties Topics Selected Topics Multimedia Selected Multimedia Current Issue Current Issue Recent Issues Recently Published Articles Learning/CME Other (...) NEJM Group Learning Keyword . Already have an account? Free Preview Treatment of Superficial Thrombophlebitis This article has no abstract; the first 100 words appear below. To the Editor: Decousus et al. (Sept. 23 issue) 1 report that fondaparinux was effective in the treatment of superficial-vein thrombosis, as compared with placebo. The authors state that hemostasis monitoring is unnecessary with fondaparinux therapy, affording an advantage over other anticoagulant treatments. In their study

2011 NEJM

12. Idiopathic superficial thrombophlebitis and the incidence of cancer in primary care patients (PubMed)

Idiopathic superficial thrombophlebitis and the incidence of cancer in primary care patients The association of spontaneous venous thromboembolism with occult malignancy is well established. Less clear is the incidence of subsequent cancer in patients with superficial thrombophlebitis. We wanted to determine the incidence of cancer after an episode of spontaneous superficial thrombophlebitis in a large general practice population.The objective of this study was to assess the incidence of newly (...) diagnosed malignancies in patients within 2 years after the diagnosis of a spontaneous episode of superficial thrombophlebitis and to compare this incidence with nonexposed matched control patients and the Dutch population. The patients and their controls were identified by a search in the electronic patient records of 5 primary health care centers in Amsterdam, the Netherlands. A standardized morbidity ratio was calculated using data of the Dutch cancer registry.A total number of 277 patients

Full Text available with Trip Pro

2010 EvidenceUpdates

13. Treatment for superficial thrombophlebitis of the leg. (PubMed)

Treatment for superficial thrombophlebitis of the leg. The optimal treatment of superficial thrombophlebitis (ST) of the legs remains poorly defined. While improving or relieving the local painful symptoms, treatment should aim at preventing venous thromboembolism (VTE), which might complicate the natural history of ST.To assess the efficacy and safety of topical, medical, and surgical treatments in patients presenting with ST of the legs.The Cochrane Peripheral Vascular Diseases Group searched (...) in the superficial vein.Two authors assessed the trials for inclusion in the review, extracted the data, and assessed the quality of the studies. Data were extracted independently from the included studies and any disagreements resolved by consensus.Twenty-four studies involving 2469 participants with ST of the legs were included in this review. The methodological quality of most of the trials was poor. Treatment ranged from low molecular weight heparin (LMWH), to non-steroidal anti-inflammatory agents (NSAIDs

Full Text available with Trip Pro

2007 Cochrane

14. Treatment for superficial thrombophlebitis of the leg. (PubMed)

Treatment for superficial thrombophlebitis of the leg. The optimal treatment of superficial thrombophlebitis (ST) of the legs remains poorly defined. While improving or relieving the local painful symptoms, treatment should aim at preventing venous thromboembolism (VTE), which might complicate the natural history of ST.To assess the efficacy and safety of topical, medical, and surgical treatments in patients presenting with ST of the legs.The Cochrane Peripheral Vascular Diseases Group searched (...) in the superficial vein.Two authors assessed the trials for inclusion in the review, extracted the data, and assessed the quality of the studies. Data were extracted independently from the included studies and any disagreements resolved by consensus.Twenty-four studies involving 2469 participants with ST of the legs were included in this review. The methodological quality of most of the trials was poor. Treatment ranged from low molecular weight heparin (LMWH), to non-steroidal anti-inflammatory agents (NSAIDs

2007 Cochrane